Roivant Is Striving Towards New Standards Of Care
Firm Has A Busy 2023 Ahead With Several Promising Data Readouts Expected
With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.
You may also be interested in...
The company wants to focus efforts with the TYK2/JAK1 inhibitor in orphan rheumatology indications like dermatomyositis where current treatment options are inadequate.
In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.